Back

Comparative effectiveness of ventricular tachycardia ablation versus escalated antiarrhythmic drug therapy by location of myocardial infarction: A sub-study of the VANISH trial

23 April 2021 (16:00 - 22:20)
Organised by:
Congress Presentation Part of: Oral abstract session - Atrial fibrillation and arrhythmias Catheter Ablation of Arrhythmias EHRA Premium Access EHRA 2021

About the speaker

Photo
Associate Professor Michelle Samuel

Allegheny Health Network, Pittsburgh (United States of America)

12 More presentations in this session

Presentation thumbnail
Clinical and electrophysiological characteristics of extra-pulmonary vein triggers in patients who underwent catheter ablation for atrial fibrillation
Doctor T. Hwang (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation detected at screening is not a benign condition - a comparison of clinical outcomes in screen-detected vs. hospital-detected atrial fibrillation
Mr V. Zwartkruis (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Personalized atrial fibrillation ablation by tailoring ablation index to the left atrial wall thickness. the ablate by-law single center study.
Doctor C. Teres (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation in the young: clinical characteristics, predictors of new onset and outcomes
Doctor A. Segev (Vancouver, CA)
Abstract Slides Video
Presentation thumbnail
Grayzone myocardial fibrosis and ventricular arrhythmias in patients with a left ventricular ejection fraction greater than 35%
Doctor A. Zegard (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Oral abstract session - Atrial fibrillation and arrhythmias

The Event

Event poster

EHRA 2021

23 April 2021 16:00 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources